• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Medrad annual revenues up 9%

Article

Medrad last week announced financial results for its fiscal 1995 (end-January) that saw revenues increase9% and net earnings up as well. The Pittsburgh-based company recordedrevenues for the fiscal year of $78.3 million, compared to $71.7million in the

Medrad last week announced financial results for its fiscal 1995 (end-January) that saw revenues increase9% and net earnings up as well. The Pittsburgh-based company recordedrevenues for the fiscal year of $78.3 million, compared to $71.7million in the prior year. Net earnings in 1995 will be approximately$1.15 per share, compared to 92¢ per share for the same perioda year ago.

Medrad also announced that it has created separate businessunits for its two major businesses, vascular injection systemsand MRI surface coil products. Each unit will have its own dedicatedmanagement team and new product development functions, the companyreported.

Related Videos
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Related Content
© 2024 MJH Life Sciences

All rights reserved.